Novartis Home

At Novartis, we are reimagining medicine

Transmission electron microscopic image of an isolate from a case of COVID-19

Novartis COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.

Enter

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish compassionate use program

Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP trial

News Feed

Environmental, Social and Governance (ESG) Index

Novartis aims to report comprehensively and transparently about ESG topics. We have created the Novartis ESG Index to signpost where our key disclosures can be found across our publications and channels.

Annual Review cover with young boy playing

Annual Review 2019

The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2019.

Learn More

Cell & Gene Therapy at Novartis

We are reimagining medicine to power breakthrough innovation in cell and gene therapy.

Learn More

Novartis Home

At Novartis, we are reimagining medicine

Novartis COVID-19 Information Center

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish compassionate use program

Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP trial

Environmental, Social and Governance (ESG) Index

Annual Review 2019

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

Cell & Gene Therapy at Novartis